Scarica l'app Stockscreener
2.32
18.60%
-0.53
Pre-mercato:
2.52
0.20
+8.62%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché CABA Giù?
Forum
Previsione
Precedente Chiudi:
$2.85
Aprire:
$3.15
Volume 24 ore:
14.54M
Relative Volume:
6.28
Capitalizzazione di mercato:
$212.20M
Reddito:
-
Utile/perdita netta:
$-67.68M
Rapporto P/E:
-1.3976
EPS:
-1.66
Flusso di cassa netto:
$-54.24M
1 W Prestazione:
-4.92%
1M Prestazione:
+33.33%
6M Prestazione:
+112.84%
1 anno Prestazione:
-41.27%
Intervallo 1D:
$2.2301
$3.1599
Intervallo di 1 settimana:
$2.2301
$3.34
Portata 52W:
$0.9857
$5.46
Cabaletta Bio Inc Stock (CABA) Company Profile
Nome
Cabaletta Bio Inc
Settore
Industria
Telefono
(267) 759-3100
Indirizzo
2929 ARCH STREET, PHILADELPHIA, PA
Confronta CABA con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
CABA
Cabaletta Bio Inc
|
2.32 | 260.68M | 0 | -67.68M | -54.24M | -1.66 |
|
VRTX
Vertex Pharmaceuticals Inc
|
407.79 | 106.37B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
460.46 | 59.90B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
564.63 | 60.40B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
796.92 | 49.56B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
320.10 | 36.88B | 4.56B | -176.77M | 225.30M | -1.7177 |
Cabaletta Bio Inc Stock (CABA) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-10-10 | Ripresa | Jefferies | Buy |
| 2024-12-20 | Downgrade | Evercore ISI | Outperform → In-line |
| 2024-12-19 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2024-10-10 | Iniziato | UBS | Buy |
| 2024-02-05 | Iniziato | Jefferies | Buy |
| 2023-11-29 | Iniziato | William Blair | Outperform |
| 2023-10-24 | Iniziato | Cantor Fitzgerald | Overweight |
| 2023-10-19 | Iniziato | Stifel | Buy |
| 2023-09-05 | Iniziato | Citigroup | Buy |
| 2023-07-18 | Iniziato | Guggenheim | Buy |
| 2023-01-27 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2022-08-30 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2021-12-08 | Iniziato | Wells Fargo | Overweight |
| 2021-10-19 | Ripresa | Morgan Stanley | Overweight |
| 2021-06-30 | Iniziato | Mizuho | Buy |
| 2021-01-08 | Iniziato | Chardan Capital Markets | Buy |
| 2020-10-13 | Iniziato | H.C. Wainwright | Buy |
| 2019-11-19 | Iniziato | Cowen | Outperform |
| 2019-11-19 | Iniziato | Evercore ISI | Outperform |
| 2019-11-19 | Iniziato | Morgan Stanley | Overweight |
Mostra tutto
Cabaletta Bio Inc Borsa (CABA) Ultime notizie
Measuring Cabaletta Bio Inc.’s beta against major indicesMarket Performance Report & AI Forecast for Swing Trade Picks - newser.com
Cabaletta Bio Inc. stock trendline breakdown2025 Geopolitical Influence & Expert-Curated Trade Recommendations - newser.com
Cabaletta Bio (NASDAQ:CABA) Coverage Initiated by Analysts at Jefferies Financial Group - MarketBeat
Cabaletta Bio (NASDAQ:CABA) Given Buy Rating at HC Wainwright - MarketBeat
Jefferies resumes coverage on Cabaletta Bio stock with Buy rating By Investing.com - Investing.com Canada
Can Cabaletta Bio Inc. stock surprise with earnings upside2025 Sector Review & AI Based Buy/Sell Signal Reports - newser.com
Morning Market Movers: INTS, SHPH, CARM Spark Moves - RTTNews
Cabaletta Bio stock rating reiterated at Overweight by Cantor Fitzgerald - Investing.com Nigeria
HC Wainwright & Co. Reiterates Buy Rating for CABA with $16 Pric - GuruFocus
Jefferies resumes coverage on Cabaletta Bio stock with Buy rating - Investing.com
Can Cabaletta Bio Inc. stock outperform in 2025 bull marketJuly 2025 Recap & Expert Curated Trade Ideas - newser.com
Will Cabaletta Bio Inc. benefit from macro trendsWeekly Trend Report & Smart Swing Trading Alerts - newser.com
Cabaletta Bio's (CABA) "Sell (D-)" Rating Reiterated at Weiss Ratings - MarketBeat
Cabaletta Bio (CABA) Shares Surge 30% After Promising Pemphigus Vulgaris Data - GuruFocus
Cabaletta Bio, Inc. Presents First Rese-cel Data with No Pre Conditioning Demonstrating Biologic Activity and Early Clinical Responses at the 2025 ESGCT Annual Congress - MarketScreener
Cabaletta Bio (CABA) Reports Positive Initial Results from RESET-PV Trial - GuruFocus
Cabaletta Bio Inc reports new data from RESET-PV trial - MarketScreener
Cabaletta Bio Reports Promising Initial Data from RESET-PV Trial of Rese-cel in Pemphigus Vulgaris Without Preconditioning - Quiver Quantitative
Cabaletta Bio Presents First Rese-cel Data with No Preconditioning Demonstrating Biologic Activity and Early Clinical Responses at the 2025 ESGCT Annual Congress - The Manila Times
What the charts say about Cabaletta Bio Inc. today2025 Trading Volume Trends & Fast Moving Trade Plans - newser.com
What candlestick patterns are forming on Cabaletta Bio Inc.July 2025 Gainers & Precise Buy Zone Identification - newser.com
Published on: 2025-10-09 01:46:57 - newser.com
How to use Fibonacci retracement on Cabaletta Bio Inc.July 2025 Sector Moves & Stepwise Entry/Exit Trade Alerts - newser.com
Myasthenia Gravis Pipeline 2025: FDA Updates, Therapy Innovations, and Clinical Trial Landscape Analysis by DelveInsight | Alpine Immune Science, Toleranzia, Cabaletta Bio, Rallybio, Alexion Pharma - Barchart.com
Cabaletta Bio: Still Optimistic, With News Being Guided To Share Soon (CABA) - Seeking Alpha
Using fundamentals and technicals on Cabaletta Bio Inc.July 2025 Recap & Capital Efficiency Focused Ideas - newser.com
Detecting price anomalies in Cabaletta Bio Inc. with AIPortfolio Growth Summary & Consistent Profit Focused Trading Strategies - newser.com
Cabaletta Bio Advances Autoimmune Therapy, Sets Strategic Goals for 2025 - MSN
Published on: 2025-10-01 06:55:18 - newser.com
Cabaletta Bio Updates Progress on RESET-Myositis Trial and Regulatory Milestones - MSN
Published on: 2025-09-29 01:01:46 - newser.com
Cabaletta Bio Reports Q3 2024 Financial Results and Clinical Trial Advancements - MSN
What analysts say about Cabaletta Bio Inc stockEarnings Beat Highlights & Outstanding Portfolio Tips - earlytimes.in
Cabaletta Bio Inc Azioni (CABA) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
5.74%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):